China, U.S. Agree On Ensuring Defective Drugs Not Sent to U.S. (China)
This article was originally published in PharmAsia News
Executive Summary
U.S. and Chinese drug authorities reached an agreement at a summit meeting on safety issues designed to ensure China will not export defective food or drugs to the United States. The drug and medical equipment agreement also requires U.S. authorities to notify Chinese counterparts of recalls, warning letters and reports on adverse side effects. The two sides also agreed to joint investigations by their respective FDAs of suspected companies when defective products are discovered. Implementation details are to be worked out over the next four months. (Click here for more ) "Pact On Drugs, Equipment Safety Inked" China Daily (12/13/07)
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.